Antibody responses to immunoevasion proteins BBK32 and OspE constitute part of the serological footprint in neuroborreliosis but are insufficient to prevent the disease.
Humans
Lyme Neuroborreliosis
/ immunology
Antibodies, Bacterial
/ blood
Bacterial Outer Membrane Proteins
/ immunology
Middle Aged
Female
Male
Adult
Aged
Borrelia burgdorferi
/ immunology
Antigens, Bacterial
/ immunology
Virulence Factors
/ immunology
Immunoglobulin G
/ blood
Chemokine CXCL13
/ blood
Bacterial Proteins
/ immunology
Antibody Formation
/ immunology
Borrelia burgdorferi sensu lato
Borrelia garinii
BBK32
CXCL13
OspE
neuroborreliosis
Journal
Scandinavian journal of immunology
ISSN: 1365-3083
Titre abrégé: Scand J Immunol
Pays: England
ID NLM: 0323767
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
revised:
14
11
2023
received:
01
07
2023
accepted:
21
12
2023
medline:
15
7
2024
pubmed:
15
7
2024
entrez:
15
7
2024
Statut:
ppublish
Résumé
Lyme borreliosis, caused by Borrelia burgdorferi sensu lato, is the most common tickborne disease. Its neuronal form, neuroborreliosis, comprises 3 to 38% of borreliosis cases in Europe. Borrelia outer surface proteins and virulence factors, OspE and BBK32, have been previously reported to help cause infection by promoting attachment to human host epithelial cells and evading complement attack. We assessed the serological responses to BBK32 and OspE in 19 individuals diagnosed with neuroborreliosis to see whether antibodies that could both target the bacteria and neutralize the virulence mechanisms on the microbial surface emerge. Results evaluate levels of total protein, IgG and the chemokine CXCL13, a determinant for B-cell recruitment during neuroinflammation, in patients' cerebrospinal fluid samples. Antibody levels against BBK32 and OspE correlated with those against VlsE, a well-characterized diagnostic serological marker of the disease. A dual serological profile of the patients was observed. K-means clustering split the cohort into two discrete groups presenting distinct serological and CNS responses. One group contained young patients with low levels of anti-BBK32 and OspE antibodies. The other group showed stronger responses, possibly following prolonged infections or reinfections. Additionally, we assessed anti-ganglioside antibodies that could cause autoimmunity or complement dysregulation but observed that they did not correlate with neuroborreliosis in our patient cohort. The dual nature of antibody responses against the virulence factors BBK32 and OspE in neuroborreliosis patients may suggest the necessity of repeated exposures for efficient immune responses. Better protection could be achieved if the virulence factors were formulated into vaccines.
Substances chimiques
Antibodies, Bacterial
0
Bacterial Outer Membrane Proteins
0
Antigens, Bacterial
0
Virulence Factors
0
Immunoglobulin G
0
Chemokine CXCL13
0
Bacterial Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13353Subventions
Organisme : Special State Subsidy for Health Research at Helsinki University Hospital
Organisme : Sigrid Juséliuksen Säätiö
Organisme : Jane ja Aatos Erkon Säätiö
Informations de copyright
© 2024 The Authors. Scandinavian Journal of Immunology published by John Wiley & Sons Ltd on behalf of The Scandinavian Foundation for Immunology.
Références
Sykes RA, Makiello P. An estimate of Lyme borreliosis incidence in Western Europe. J Public Health (Oxf). 2017;39:74‐81. doi:10.1093/pubmed/fdw017
Petrulionienė A, Radzišauskienė D, Ambrozaitis A, Čaplinskas S, Paulauskas A, Venalis A. Epidemiology of Lyme disease in a highly endemic European zone. Medicina (B Aires). 2020;56:115. doi:10.3390/MEDICINA56030115
Hvidsten D, Frafjord K, Gray JS, et al. The distribution limit of the common tick, Ixodes ricinus, and some associated pathogens in North‐Western Europe. Ticks Tick Borne Dis. 2020;11:101388. doi:10.1016/J.TTBDIS.2020.101388
Jaenson TGT, Jaenson DGE, Eisen L, Petersson E, Lindgren E. Changes in the geographical distribution and abundance of the tick Ixodes ricinus during the past 30 years in Sweden. Parasit Vectors. 2012;5:1‐15. doi:10.1186/1756-3305-5-8/TABLES/2
Alkishe AA, Peterson AT, Samy AM. Climate change influences on the potential geographic distribution of the disease vector tick Ixodes ricinus. PLoS One. 2017;12:e0189092. doi:10.1371/journal.pone.0189092
Li S, Gilbert L, Vanwambeke SO, Yu J, Purse BV, Harrison PA. Lyme disease risks in Europe under multiple uncertain drivers of change. Environ Health Perspect. 2019;127:67010. doi:10.1289/EHP4615
Hubálek Z. Epidemiology of Lyme borreliosis. Curr Probl Dermatol. 2009;37:31‐50. doi:10.1159/000213069
Hofhuis A, Harms M, Bennema S, Van Den Wijngaard CC, Van Pelt W. Physician reported incidence of early and late Lyme borreliosis. Parasit Vectors. 2015;8:1‐8. doi:10.1186/S13071-015-0777-6/FIGURES/2
Theel ES. Tickborne Borrelia infections: beyond just Lyme disease. Clin Lab Med. 2015;35:ix‐x. doi:10.1016/J.CLL.2015.09.001
Radolf J, Caimano M, Stevenson B, Hu LT. Of ticks, Mice and men: understanding the dual‐host lifestyle of Lyme disease Spirochaetes. Nat Rev Microbiol. 2012;10:87‐99.
Fingerle V, Schulte‐Spechtel UC, Ruzic‐Sabljic E, et al. Epidemiological aspects and molecular characterization of Borrelia burgdorferi s.l. from southern Germany with special respect to the new species Borrelia spielmanii sp. nov. Int J Med Microbiol. 2008;298:279‐290. doi:10.1016/j.ijmm.2007.05.002
Garcia‐Monco JC, Benach JL. Lyme Neuroborreliosis: clinical outcomes, controversy, pathogenesis, and Polymicrobial infections. Ann Neurol. 2019;85:21‐31. doi:10.1002/ANA.25389
Dryden MS, Saeed K, Ogborn S, Swales P. Lyme borreliosis in southern United Kingdom and a case for a new syndrome, chronic arthropod‐borne neuropathy. Epidemiol Infect. 2015;143:561‐572. doi:10.1017/S0950268814001071
Vandenesch A, Turbelin C, Couturier E, et al. Incidence and hospitalisation rates of Lyme borreliosis, France, 2004 to 2012. Eurosurveillance. 2014;19:20883. doi:10.2807/1560-7917.ES2014.19.34.20883/CITE/PLAINTEXT
Hofhuis A, Harms M, Bennema S, Van Den Wijngaard CC, Van Pelt W. Physician reported incidence of early and late Lyme borreliosis. Parasit Vectors. 2015;8:161. doi:10.1186/S13071-015-0777-6
Dahl V, Wisell KT, Giske CG, Tegnell A, Wallensten A. Lyme neuroborreliosis epidemiology in Sweden 2010 to 2014: clinical microbiology laboratories are a better data source than the hospital discharge diagnosis register. Eurosurveillance. 2019;24:1800453. doi:10.2807/1560-7917.ES.2019.24.20.1800453/CITE/PLAINTEXT
Dessau RB, Espenhain L, Mølbak K, Krause TG, Voldstedlund M. Improving national surveillance of Lyme neuroborreliosis in Denmark through electronic reporting of specific antibody index testing from 2010 to 2012. Eurosurveillance. 2015;20:21184. doi:10.2807/1560-7917.ES2015.20.28.21184/CITE/PLAINTEXT
van den Wijngaard CC, Hofhuis A, Simões M, et al. Surveillance perspective on Lyme borreliosis across the European Union and European economic area. Eurosurveillance. 2017;22:30569. doi:10.2807/1560-7917.ES.2017.22.27.30569/CITE/PLAINTEXT
Wilking H, Stark K. Trends in surveillance data of human Lyme borreliosis from six federal states in eastern Germany, 2009–2012. Ticks Tick Borne Dis. 2014;5:219‐224. doi:10.1016/J.TTBDIS.2013.10.010
Kullberg BJ, Vrijmoeth HD, Van De Schoor F, Hovius JW. Lyme borreliosis: diagnosis and management. BMJ. 2020;369:m1041. doi:10.1136/BMJ.M1041
Rauer S, Kastenbauer S, Fingerle V, Hunfeld KP, Huppertz HI, Dersch R. Lyme Neuroborreliosis. Dtsch Arztebl Int. 2018;115:751‐756. doi:10.3238/ARZTEBL.2018.0751
Berger BW. Dermatologic manifestations of Lyme disease. Rev Infect Dis. 1989;11(Suppl 6):S1475‐S1481. doi:10.1093/CLINIDS/11.SUPPLEMENT_6.S1475
Donta ST. What we know and Don't know about Lyme disease. Front Public Health. 2022;9:2331. doi:10.3389/FPUBH.2021.819541/BIBTEX
Backman K, Skogman BH. Occurrence of erythema migrans in children with Lyme neuroborreliosis and the association with clinical characteristics and outcome – a prospective cohort study. BMC Pediatr. 2018;18:189. doi:10.1186/S12887-018-1163-2
Feuth E, Virtanen M, Helve O, Hytönen J, Sane J. Lyme borreliosis in Finland: a register‐based linkage study. BMC Infect Dis. 2020;20:1‐8. doi:10.1186/S12879-020-05555-W/TABLES/1
Müller T, Locht H, Panum I, Nielsen L, Jensen B. Lyme arthritis is rare in eastern Denmark. Original Article Dan Med J. 2021;68:5210423.
Hellwage J, Meri T, Heikkilä T, et al. The complement regulator factor H binds to the surface protein OspE of Borrelia burgdorferi. Journal of Biological Chemistry. 2001;276:8427‐8435. doi:10.1074/jbc.M007994200
Kraiczy P, Skerka C, Brade V, Zipfel PF. Further characterization of complement regulator‐acquiring surface proteins of Borrelia burgdorferi. Infect Immun. 2001;69:7800‐7809. doi:10.1128/IAI.69.12.7800-7809.2001
Alitalo A, Meri T, Rämö L, et al. Complement evasion by Borrelia burgdorferi: serum‐resistant strains promote C3b inactivation. Infect Immun. 2001;69:3685‐3691. doi:10.1128/IAI.69.6.3685-3691.2001
Alitalo A, Meri T, Comstedt P, et al. Expression of complement factor H binding immunoevasion proteins in Borrelia garinii isolated from patients with neuroborreliosis. Eur J Immunol. 2005;35:3043‐3053. doi:10.1002/EJI.200526354
Garcia BL, Zhi H, Wager B, Höök M, Skare JT. Borrelia burgdorferi BBK32 inhibits the classical pathway by blocking activation of the C1 complement complex. PLoS Pathog. 2016;12:e1005404. doi:10.1371/JOURNAL.PPAT.1005404
Eldin C, Raffetin A, Bouiller K, et al. Review of European and American guidelines for the diagnosis of Lyme borreliosis. Med Mal Infect. 2019;49:121‐132. doi:10.1016/J.MEDMAL.2018.11.011
Perronne C, Publique A, De H, et al. A practical approach to the diagnosis of Lyme Borreliosis: from clinical heterogeneity to laboratory methods. Front Med. 2020;1:265. doi:10.3389/fmed.2020.00265
Marques AR. Laboratory diagnosis of Lyme disease ‐ advances and challenges. Infect Dis Clin North Am. 2015;29:295‐307. doi:10.1016/J.IDC.2015.02.005
Skufca J, De Smedt N, Pilz A, et al. Incidence of Lyme Borreliosis in Finland: exploring observed trends over time using public surveillance data, 2015–2020. Vector Borne Zoonotic Dis. 2023;23:256‐264. doi:10.1089/VBZ.2022.0047
Hauser U, Lehnert G, Wilske B. Diagnostic value of proteins of three Borrelia species (Borrelia burgdorferi Sensu Lato) and implications for development and use of recombinant antigens for Serodiagnosis of Lyme Borreliosis in Europe. Clin Diagn Lab Immunol. 1998;5:456‐462. doi:10.1128/CDLI.5.4.456-462.1998
Talagrand‐Reboul E, Raffetin A, Zachary P, Jaulhac B, Eldin C. Immunoserological diagnosis of human Borrelioses: current knowledge and perspectives. Front Cell Infect Microbiol. 2020;10:241. doi:10.3389/FCIMB.2020.00241/BIBTEX
Mygland Å, Ljøstad U, Fingerle V, Rupprecht T, Schmutzhard E, Steiner I. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol. 2010;17:8‐16. doi:10.1111/J.1468-1331.2009.02862.X
Cepok S, Zhou D, Vogel F, et al. The immune response at onset and during recovery from Borrelia burgdorferi meningoradiculitis. Arch Neurol. 2003;60:849‐855. doi:10.1001/ARCHNEUR.60.6.849
Rupprecht TA, Kirschning CJ, Popp B, et al. Borrelia garinii induces CXCL13 production in human monocytes through toll‐like receptor 2. Infect Immun. 2007;75:4351‐4356. doi:10.1128/IAI.01642-06
Rupprecht T, Koedel U, Angele B, Fingerle V, Pfister HW. Cytokine CXCL13—a possible early CSF marker for neuroborreliosis. Nervenarzt. 2006;77:470‐473. doi:10.1007/S00115-005-2021-7
Tetens MM, Dessau R, Ellermann‐Eriksen S, et al. The diagnostic value of serum Borrelia burgdorferi antibodies and seroconversion after Lyme neuroborreliosis, a nationwide observational study. Clin Microbiol Infec. 2022;28:1500.e1‐1500.e6. doi:10.1016/J.CMI.2022.06.001
Prion S, Haerling KA. Making sense of methods and measurement: spearman‐rho ranked‐order correlation coefficient. Clin Simul Nurs. 2014;10:535‐536. doi:10.1016/J.ECNS.2014.07.005
Leclezio L, Jansen A, Whittemore VH, De Vries PJ. Pilot validation of the tuberous sclerosis‐associated neuropsychiatric disorders (TAND) checklist. Pediatr Neurol. 2015;52:16‐24. doi:10.1016/J.PEDIATRNEUROL.2014.10.006
Yan Z, Wang S, Ma D, Liu B, Lin H, Li S. Meteorological factors affecting pan evaporation in the Haihe River basin, China. Water. 2019;11:317. doi:10.3390/W11020317
Jahan M. Assessment of knowledge, attitude and practices towards gender equality in achieving SDG5. J Ind Sustain Dev Plan. 2021;2:290‐306. doi:10.46456/JISDEP.V2I3.209
Jovanovic D, Atanasievska S, Protic‐Djokic V, Rakic U, Lukac‐Radoncic E, Ristanovic E. Seroprevalence of Borrelia burgdorferi in occupationally exposed persons in the Belgrade area, Serbia. Braz J Microbiol. 2015;46:807‐814. doi:10.1590/S1517-838246320140698
Pulzova L, Bhide M. Outer surface proteins of Borrelia: peerless immune evasion tools. Curr Protein Pept Sci. 2014;15:75‐88. doi:10.2174/1389203715666140221124213
Heikkilä T, Huppertz HI, Seppälä I, Sillanpää H, Saxen H, Lahdenne P. Recombinant or peptide antigens in the serology of Lyme arthritis in children. J Infect Dis. 2003;187:1888‐1894. doi:10.1086/375371
Roberts WC, Mullikin BA, Lathigra R, Hanson MS. Molecular analysis of sequence heterogeneity among genes encoding decorin binding proteins a and B of Borrelia burgdorferi sensu lato. Infect Immun. 1998;66:5275‐5285. doi:10.1128/IAI.66.11.5275-5285.1998
Moncó JCG, Wheeler CM, Benach JL, et al. Reactivity of neuroborreliosis patients (Lyme disease) to cardiolipin and gangliosides. J Neurol Sci. 1993;117:206‐214. doi:10.1016/0022-510X(93)90175-X
Palmano K, Rowan A, Guillermo R, Guan J, McJarrow P. The role of gangliosides in neurodevelopment. Nutrients. 2015;7:3891‐3913. doi:10.3390/NU7053891
Cutillo G, Saariaho AH, Meri S. Physiology of gangliosides and the role of antiganglioside antibodies in human diseases. Cellular & Molecular Immunology. 2020;17:313‐322. doi:10.1038/s41423-020-0388-9
Legler DF, Loetscher M, Roos RS, Clark‐Lewis I, Baggiolini M, Moser B. B cell–attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med. 1998;187:655‐660. doi:10.1084/JEM.187.4.655
Eckman EA, Clausen DM, Herdt AR, Pacheco‐Quinto J, Halperin JJ. Specificity and diagnostic utility of cerebrospinal fluid CXCL13 in Lyme Neuroborreliosis. Clin Infect Dis. 2021;72:1719‐1726. doi:10.1093/CID/CIAA335
Rupprecht TA, Manz KM, Fingerle V, et al. Diagnostic value of cerebrospinal fluid CXCL13 for acute Lyme neuroborreliosis. A systematic review and meta‐analysis. Clin Microbiol Infect. 2018;24:1234‐1240. doi:10.1016/J.CMI.2018.04.007
Kowarik MC, Cepok S, Sellner J, et al. CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J Neuroinflammation. 2012;9:1‐11. doi:10.1186/1742-2094-9-93/TABLES/3
Wu Q, Guan G, Liu Z, Li Y, Luo J, Yin H. RNA‐Seq‐based analysis of changes in Borrelia burgdorferi gene expression linked to pathogenicity. Parasit Vectors. 2015;8:1‐6. doi:10.1186/S13071-014-0623-2/FIGURES/4
Hefty PS, Jolliff SE, Caimano MJ, Wikel SK, Radolf JD, Akins DR. Regulation of OspE‐related, OspF‐related, and Elp lipoproteins of Borrelia burgdorferi strain 297 by mammalian host‐specific signals. Infect Immun. 2001;69:3618‐3627. doi:10.1128/IAI.69.6.3618-3627.2001
Strle F, Ružić‐Sabljić E, Cimperman J, Lotrič‐Furlan S, Maraspin V. Comparison of findings for patients with Borrelia garinii and Borrelia afzelii isolated from cerebrospinal fluid. Clin Infect Dis. 2006;43:704‐710. doi:10.1086/506936/2/43-6-704-TBL005.GIF
Jahfari S, Krawczyk A, Coipan EC, et al. Enzootic origins for clinical manifestations of Lyme borreliosis. Infect, Genet Evol. 2017;49:48‐54. doi:10.1016/J.MEEGID.2016.12.030
Laaksonen M, Klemola T, Feuth E, et al. Tick‐borne pathogens in Finland: comparison of Ixodes ricinus and I. Persulcatus in sympatric and parapatric areas. Parasit Vectors. 2018;11:1‐13. doi:10.1186/S13071-018-3131-Y/TABLES/4
Mäkinen J, Vuorinen I, Oksi J, et al. Prevalence of granulocytic Ehrlichia and Borrelia burgdorferi sensu lato in Ixodes ricinus ticks collected from southwestern Finland and from Vormsi Island in Estonia. APMIS. 2003;111:355‐362. doi:10.1034/J.1600-0463.2003.1110209.X
Rauter C, Hartung T. Prevalence of Borrelia burgdorferi Sensu Lato Genospecies in Ixodes ricinus ticks in Europe: a Metaanalysis. Appl Environ Microbiol. 2005;71:7203‐7216. doi:10.1128/AEM.71.11.7203-7216.2005
Junttila J, Peltomaa M, Soini H, Marjamäki M, Viljanen MK. Prevalence of Borrelia burgdorferi in Ixodes ricinus ticks in urban recreational areas of Helsinki. J Clin Microbiol. 1999;37:1361‐1365. doi:10.1128/JCM.37.5.1361-1365.1999
Barstad B, Quarsten H, Tveitnes D, et al. Direct molecular detection and genotyping of Borrelia burgdorferi Sensu Lato in cerebrospinal fluid of children with Lyme Neuroborreliosis. J Clin Microbiol. 2018;56:e01868‐17. doi:10.1128/JCM.01868-17
Coipan EC, Jahfari S, Fonville M, et al. Imbalanced presence of Borrelia burgdorferi s.l. multilocus sequence types in clinical manifestations of Lyme borreliosis. Infect Genet Evol. 2016;42:66‐76. doi:10.1016/J.MEEGID.2016.04.019
Donta ST. Issues in the diagnosis and treatment of Lyme disease. Open Neurol J. 2012;6:140‐145. doi:10.2174/1874205X01206010140
Shadick NA, Phillips CB, Logigian EL, et al. The long‐term clinical outcomes of Lyme disease: a population‐based retrospective cohort study. Ann Intern Med. 1994;121:560‐567. doi:10.7326/0003-4819-121-8-199,410,150-00002
Dulipati V, Meri S, Panelius J. Complement evasion strategies of Borrelia burgdorferi sensu lato. FEBS Lett. 2020;594:2645‐2656. doi:10.1002/1873-3468.13894
Zhi H, Xie J, Skare JT. The classical complement pathway is required to control Borrelia burgdorferi levels during experimental infection. Front Immunol. 2018;9:959. doi:10.3389/FIMMU.2018.00959/BIBTEX
Alitalo A, Meri T, Lankinen H, et al. Complement inhibitor factor H binding to Lyme disease spirochetes is mediated by inducible expression of multiple plasmid‐encoded outer surface protein E paralogs. J Immunol. 2002;169:3847‐3853. doi:10.4049/JIMMUNOL.169.7.3847
Stevenson B, El‐Hage N, Hines MA, Miller JC, Babb K. Differential binding of host complement inhibitor factor H by Borrelia burgdorferi Erp surface proteins: a possible mechanism underlying the expansive host range of Lyme disease spirochetes. Infect Immun. 2002;70:491‐497. doi:10.1128/IAI.70.2.491-497.2002
Kraiczy P, Hellwage J, Skerka C, et al. Immune evasion of Borrelia burgdorferi: mapping of a complement‐inhibitor factor H‐binding site of BbCRASP‐3, a novel member of the Erp protein family. Eur J Immunol. 2003;33:697‐707. doi:10.1002/EJI.200323571
Brooks CS, Vuppala SR, Jett AM, Alitalo A, Meri S, Akins DR. Complement regulator‐acquiring surface protein 1 imparts resistance to human serum in Borrelia burgdorferi. J Immunol. 2005;175:3299‐3308. doi:10.4049/JIMMUNOL.175.5.3299
Fikrig E, Barthold SW, Sun W, Feng W, Telford SR, Flavell RA. Borrelia burgdorferi P35 and P37 proteins, expressed in vivo, Elicit Protective Immunity. Immunity. 1997;6:531‐539. doi:10.1016/S1074-7613(00)80341-6
Panelius J, Meri T, Seppälä I, Eholuoto M, Alitalo A, Meri S. Outer surface protein E antibody response and its effect on complement factor H binding to OspE in Lyme borreliosis. Microbes Infect. 2008;10:135‐142. doi:10.1016/J.MICINF.2007.10.016
Panelius J, Ranki A, Meri T, Seppälä I, Meri S. Expression and sequence diversity of the complement regulating outer surface protein E in Borrelia afzelii vs. Borrelia garinii in patients with erythema migrans or neuroborreliosis. Microb Pathog. 2010;49:363‐368. doi:10.1016/J.MICPATH.2010.06.006
Shen L, Zheng J, Wang Y, et al. Increased activity of the complement system in cerebrospinal fluid of the patients with non‐HIV Cryptococcal meningitis. BMC Infect Dis. 2017;17:7. doi:10.1186/S12879-016-2107-9
Dalakas MC, Alexopoulos H, Spaeth PJ. Complement in neurological disorders and emerging complement‐targeted therapeutics. Nat Rev Neurol. 2020;16:601‐617. doi:10.1038/s41582-020-0400-0